News
The two biggest weight-loss drugmakers have lost $252bn in value this year, as investor enthusiasm for obesity treatments ...
Eli Lilly's obesity drugs delivered 38% revenue growth in the second quarter; but its oral GLP-1 candidate fell short, ...
The US drugmaker Eli Lilly has bowed to demands from Donald Trump by raising the prices of its weight-loss jab for UK ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results